At the recent SEC meeting for Dermatology and Allergy held on 5th September 2024, the expert panel reviewed a proposal for a ...

There are already several JAK inhibitors on the market – including Pfizer's own Xeljanz (abrocitinib) – while the TYK2 category is being led by Bristol-Myers Squibb's deucravacitinib ...

In the last few months, Pfizer has won approvals in the EU and US for JAK inhibitor Cibinqo (abrocitinib) as a treatment for moderate-to-severe atopic dermatitis in adults who cannot get relief ...

Abrocitinib has a manageable long-term safety profile among ... Disclosure: This study was funded by Pfizer, Inc. Some of the study authors declared affiliations with biotech, pharmaceutical, and/or ...

Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical ...

Pfizer's RSI is trending upward, bouncing from the 50 support level, signaling potential stock strength and accumulation. Pfizer's KP.2-adapted COVID-19 vaccine received FDA approval, positioning ...

Pfizer (PFE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...

Pfizer is a global pharmaceutical giant with an impressive portfolio of over 350 marketed medicines, 113 experimental candidates in clinical trials, and a presence in more than 200 countries.

Pfizer Inc has inaugurated its first commercial analytics centre in Mumbai, India. This global capability centre will serve Pfizer's international markets outside the US, employing data analytics ...